# Universal Health Services (UHS) financials

Universal Health Services reported revenue of $17.4 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 9.7% from fiscal 2024. Net income was $1.49 billion and diluted earnings per share $23.10.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Sep 2026), revenue was $4.73 billion, up 5.3% from a year earlier.

Source: Universal Health Services's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 6 Nov 2026. Amounts in USD. Page: https://aapwire.com/stocks/UHS. Retrieved 2026-11-16.

## Latest results: Q3 FY2026

Universal Health Services reported revenue of $4.73 billion, up 5.3% from a year earlier, net income of $309 million and diluted earnings per share of $5.22 against $5.86 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).

From its quarterly report, the results first announced on 27 Oct 2026.

| Measure | Q3 FY2026 | Q3 FY2025 | Change |
| --- | ---: | ---: | ---: |
| Revenue | $4.73B | $4.50B | +5.3% |
| Operating income | $454.4M | $521.7M | −12.9% |
| Operating margin | 9.6% | 11.6% | −2.0 pts |
| Net income | $308.7M | $373.0M | −17.2% |
| Diluted EPS | $5.22 | $5.86 | −10.9% |
| Operating cash flow | $636.6M | $380.7M | +67.2% |
| Capital expenditure | $214.9M | $228.9M | −6.1% |
| Free cash flow | $421.6M | $151.8M | +178% |

Page: https://aapwire.com/stocks/UHS/earnings

## Annual figures (fiscal years)

| Measure | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $9.77B | $10.41B | $10.77B | $11.38B | $11.56B | $12.64B | $13.40B | $14.28B | $15.83B | $17.36B |
| Revenue growth | +8.0% | +6.6% | +3.5% | +5.6% | +1.6% | +9.4% | +6.0% | +6.6% | +10.8% | +9.7% |
| Operating income | $1.28B | $1.28B | $1.18B | $1.22B | $1.36B | $1.36B | $1.00B | $1.18B | $1.68B | $1.99B |
| Net income | $702.4M | $752.3M | $779.7M | $814.9M | $944.0M | $991.6M | $675.6M | $717.8M | $1.14B | $1.49B |
| Diluted EPS | $7.14 | $7.81 | $8.31 | $9.13 | $10.99 | $11.82 | $9.14 | $10.23 | $16.82 | $23.10 |
| Operating cash flow | $1.33B | $1.25B | $1.27B | $1.44B | $2.36B | $883.7M | $996.0M | $1.27B | $2.07B | $1.86B |
| Capital expenditure | $519.9M | $557.5M | $665.0M | $634.1M | $731.3M | $855.7M | $734.0M | $743.1M | $943.8M | $1.02B |
| Free cash flow | $813.9M | $690.1M | $609.8M | $804.4M | $1.63B | $28.04M | $262.0M | $524.7M | $1.12B | $849.2M |
| Operating margin | 13.1% | 12.3% | 10.9% | 10.7% | 11.8% | 10.8% | 7.5% | 8.2% | 10.6% | 11.5% |
| Net margin | 7.2% | 7.2% | 7.2% | 7.2% | 8.2% | 7.8% | 5.0% | 5.0% | 7.2% | 8.6% |
| Cash and equivalents | $33.75M | $74.42M | $105.2M | $61.27M | $1.22B | $115.3M | $102.8M | $119.4M | $126.0M | $137.8M |
| Total debt | $4.14B | $4.04B | $4.00B | $4.31B | $4.19B | $4.56B | $5.27B | $5.37B | $4.96B | $5.17B |
| Shareholders' equity | $4.53B | $4.99B | $5.39B | $5.50B | $6.32B | $6.09B | $5.92B | $6.15B | $6.67B | $7.28B |
| Diluted shares | 98.4M | 96.3M | 93.8M | 89.0M | 85.6M | 83.7M | 73.8M | 70.1M | 67.9M | 64.5M |
| Dividends per share | — | — | $0.40 | $0.60 | — | $0.80 | $0.80 | $0.80 | $0.80 | $0.80 |

## Quarterly figures (last eight fiscal quarters)

| Measure | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $4.11B | $4.10B | $4.28B | $4.50B | $4.49B | $4.50B | $4.64B | $4.73B |
| Revenue, year on year | +11.1% | +6.7% | +9.6% | +13.4% | +9.1% | +9.6% | +8.3% | +5.3% |
| Operating income | $472.5M | $454.8M | $500.3M | $521.7M | $517.2M | $502.9M | $516.7M | $454.4M |
| Net income | $332.4M | $316.7M | $353.2M | $373.0M | $445.9M | $348.7M | $358.4M | $308.7M |
| Diluted EPS | $4.96 | $4.80 | $5.43 | $5.86 | $7.06 | $5.65 | $5.98 | $5.22 |
| Free cash flow | $412.5M | $121.0M | $283.0M | $151.8M | $293.5M | $184.5M | $215.7M | $421.6M |

## Operating KPIs

| KPI | Latest | Period | Change on a year |
| --- | ---: | --- | --- |
| [ACUTE occupancy-licensed beds](https://aapwire.com/stocks/UHS/kpi/acute-occupancy-licensed-beds) | 62.1% | quarter to 30 Sep 2026 | down 0.5 points |
| [ACUTE occupancy-available beds](https://aapwire.com/stocks/UHS/kpi/acute-occupancy-available-beds) | 63.6% | quarter to 30 Sep 2026 | down 0.5 points |
| [ACUTE average licensed beds](https://aapwire.com/stocks/UHS/kpi/acute-average-licensed-beds) | 7,519 | quarter to 30 Sep 2026 | up 5.0% |
| [ACUTE average available beds](https://aapwire.com/stocks/UHS/kpi/acute-average-available-beds) | 7,347 | quarter to 30 Sep 2026 | up 5.1% |
| [ACUTE patient days](https://aapwire.com/stocks/UHS/kpi/acute-patient-days) | 429,842 | quarter to 30 Sep 2026 | up 4.2% |
| [Managed Care (HMO and PPOs) revenue](https://aapwire.com/stocks/UHS/kpi/managed-care-hmo-and-ppos-revenue) | $1.2B | quarter to 30 Sep 2026 | down 0.6% |
| [Medicaid revenue](https://aapwire.com/stocks/UHS/kpi/medicaid-revenue) | $797.7M | quarter to 30 Sep 2026 | up 4.1% |
| [Managed Medicaid revenue](https://aapwire.com/stocks/UHS/kpi/managed-medicaid-revenue) | $654.6M | quarter to 30 Sep 2026 | up 4.2% |
| [Managed Medicare revenue](https://aapwire.com/stocks/UHS/kpi/managed-medicare-revenue) | $576.3M | quarter to 30 Sep 2026 | up 11.6% |
| [Medicare revenue](https://aapwire.com/stocks/UHS/kpi/medicare-revenue) | $498.1M | quarter to 30 Sep 2026 | up 8.1% |
| [UK Revenue](https://aapwire.com/stocks/UHS/kpi/uk-revenue) | $299.0M | quarter to 30 Sep 2026 | up 13.0% |
| [Acute Care Hospital Services revenue](https://aapwire.com/stocks/UHS/kpi/acute-care-hospital-services-revenue) | $2.8B | quarter to 30 Sep 2026 | up 5.1% |
| [Behavioral Health Services revenue](https://aapwire.com/stocks/UHS/kpi/behavioral-health-services-revenue) | $2.0B | quarter to 30 Sep 2026 | up 5.7% |
| [State Medicaid programs revenue](https://aapwire.com/stocks/UHS/kpi/state-medicaid-programs-revenue) | $56.0M | fiscal year to 31 Dec 2025 | up 5.7% |

## Method

Each period is read from the report the company filed and checked against accounting identities; a figure that does not pass is left blank (—), never estimated. Free cash flow is operating cash flow less capital expenditure. Diluted EPS is as the company reported it, adjusted for later stock splits. Research information only, not investment advice.
